CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates dCTPase as a target for enhancing cancer treatment with nucleoside analogues. It involves high-throughput screening of compounds to develop a potent dCTPase inhibitor, TH1217, which shows promise in inducing cancer cell death.
In our ERC grant GEnetic NEtworks as a tool for anti-CAncer Drug Development we used siRNA screening and geneticnetworks to identify dCTPase being involved in DNA repair and replication.
Further studies revealed that dCTPase plays arole in the degradation of nucleoside analogues used in cancer treatment.
We then used an RNAi approach to validatedCTPase as a target to improve nucleoside analogue therapy.
The dCTPase protein was purified and we set up anenzymatic high-throughput assay to screen >6…
KAROLINSKA INSTITUTET
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Sweden, Stockholm
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
